Abstract
Melanoma is the most common form of skin cancer. According to the American Cancer Society (2016), melanoma accounts for 76,380 estimated diagnosed new cases and 10,130 deaths in the United States each year. With the increasing numbers of melanoma cases, a new oncolytic drug, Talimogene laherparepvec (TVEC), was recently approved by the Food and Drug Administration (FDA) for use in the local treatment of melanoma tumors, recurrent after initial surgery. TVEC contains an attenuated live herpes simplex 1 virus which is genetically modified to replicate inside tumors, causing rapid oncolysis. The knowledge and education of TVEC administration and proper handling is important to the nursing staff, patients, and caregivers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
